0001104659-22-111729.txt : 20221027 0001104659-22-111729.hdr.sgml : 20221027 20221027063810 ACCESSION NUMBER: 0001104659-22-111729 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20221026 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221027 DATE AS OF CHANGE: 20221027 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Merck & Co., Inc. CENTRAL INDEX KEY: 0000310158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 221918501 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-06571 FILM NUMBER: 221334806 BUSINESS ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 BUSINESS PHONE: 908-740-4000 MAIL ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 FORMER COMPANY: FORMER CONFORMED NAME: Merck & Co. Inc. DATE OF NAME CHANGE: 20091103 FORMER COMPANY: FORMER CONFORMED NAME: SCHERING PLOUGH CORP DATE OF NAME CHANGE: 19920703 8-K 1 tm2227726d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) October 27, 2022 (October 26, 2022)

Merck & Co., Inc.

(Exact name of registrant as specified in its charter)

New Jersey

(State or other jurisdiction

of incorporation)

1-6571

(Commission

File Number)

22-1918501

(I.R.S Employer

Identification No.)

126 East Lincoln Avenue, Rahway, NJ

(Address of principal executive offices)

07065

(Zip Code)

(Registrant’s telephone number, including area code) (908) 740-4000

Not Applicable

(Former name, former address and former fiscal year, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered

Common Stock ($0.50 par value)	MRK	New York Stock Exchange
0.500% Notes due 2024	MRK 24	New York Stock Exchange
1.875% Notes due 2026	MRK/26	New York Stock Exchange
2.500% Notes due 2034	MRK/34	New York Stock Exchange
1.375% Notes due 2036	MRK 36A	New York Stock Exchange

Item 2.02. Results of Operations and Financial Condition.

The following information, including the exhibits hereto, is being furnished pursuant to this Item 2.02.

Incorporated by reference is a press release issued by Merck & Co., Inc. (“Merck”) on October 27, 2022, regarding earnings for the third quarter of 2022, attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2.

This information shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and is not incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangment of Certiain Officers.

(b) Merck announced that Kenneth C. Frazier, the Executive Chairman of Merck’s Board of Directors (the “Board”) will retire from the Board, effective November 30, 2022.

In addition, on October 26, 2022, the Board unanimously elected Robert M. Davis, Merck’s current Chief Executive Officer and President as well as a Director on the Board to serve as Chairman of the Board, effective December 1, 2022.

On October 26, 2022, the Company issued a press release announcing the foregoing. The press release is attached as Exhibit 99.3 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

	Exhibit 99.1		Press release issued October 27, 2022, regarding earnings for the third quarter of 2022

	Exhibit 99.2		Certain supplemental information not included in the press release

	Exhibit 99.3		Press release issued October 26, 2022, regarding the appointment of the Chairman of the Board of Directors

	Exhibit 104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		Merck & Co., Inc.


Date: October 27, 2022	By:	/s/ Kelly E. W. Grez
		Kelly E. W. Grez
		Corporate Secretary

EX-99.1 2 tm2227726d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

News Release

FOR IMMEDIATE RELEASE

Merck Announces Third-Quarter 2022 Financial Results

Third-Quarter Results Reflect Sustained Strong Business Momentum Across Key Growth Drivers as Well as Investment and Progress in the Pipeline

Third-Quarter 2022 Worldwide Sales Were $15.0 Billion, an Increase of 14% From Third-Quarter 2021; LAGEVRIO Sales Were $436 Million; Growth Excluding LAGEVRIO Was 10%; Growth Excluding LAGEVRIO and the Impact From Foreign Exchange Was 14%; Sales Growth Favorably Impacted by COVID-19 Recovery

KEYTRUDA Sales Grew 20% to $5.4 Billion; Excluding the Impact From Foreign Exchange, Sales Grew 26%

GARDASIL/GARDASIL 9 Sales Grew 15% to $2.3 Billion; Excluding the Impact From Foreign Exchange, Sales Grew 20%

Third-Quarter 2022 GAAP EPS From Continuing Operations Was $1.28; Non-GAAP EPS Was $1.85; GAAP and Non-GAAP EPS Include $0.22 of Charges Related to Collaboration and Licensing Agreements with Moderna, Orna and Orion

Announced Positive Top-line Results From Pivotal Phase 3 STELLAR Trial Evaluating the Safety and Efficacy of Sotatercept

2022 Continuing Operations Financial Outlook:

Company Raises and Narrows Expected Full-Year 2022 Worldwide Sales To Be Between $58.5 Billion and $59.0 Billion, Reflecting Full-Year Growth of 20% to 21%, Growth of Approximately 12% Excluding LAGEVRIO; Outlook Includes Negative Impact From Foreign Exchange of Approximately 4%

Company Lowers Expected Full-Year 2022 GAAP EPS To Be Between $5.68 and $5.73

Company Raises and Narrows Expected Full-Year 2022 Non-GAAP EPS To Be Between $7.32 and $7.37, Including Negative Impact From Foreign Exchange of Approximately 4%

- 2 -

RAHWAY, N.J., Oct. 27, 2022 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2022.

“We continue to execute on our strategy, invest in leading-edge science and drive innovation as our colleagues deliver meaningful value for patients – which in turn provides value for our shareholders,” said Robert M. Davis, chief executive officer and president, Merck. “Our third quarter results demonstrate exceptional revenue and underlying earnings growth and sustained performance across our key growth drivers. Inspired by our purpose of saving and improving lives around the world, I am confident we are well-positioned to continue to deliver strong operational performance.”

Financial Summary

	Third Quarter
$ in millions, except EPS amounts	2022		2021		Change			Change Ex-Exchange
Sales	$	14,959	$	13,154		14	%		18	%
GAAP net income¹		3,248		4,567		-29	%		-25	%
Non-GAAP net income that excludes certain items^1,2*		4,703		4,525		4	%		7	%
GAAP EPS		1.28		1.80		-29	%		-25	%
Non-GAAP EPS that excludes certain items^2*		1.85		1.78		4	%		7	%

*Refer to table on page 11.

Generally accepted accounting principles (GAAP) earnings per share (EPS) assuming dilution was $1.28 for the third quarter of 2022. Non-GAAP EPS of $1.85 for the third quarter of 2022 excludes acquisition- and divestiture-related costs and restructuring costs, as well as income and losses from investments in equity securities. In 2022, the company changed the treatment of certain items for purposes of its non-GAAP reporting. Results for 2021 have been recast to conform to the new presentation. For more information, refer to the Form 8-K filed by the company on April 21, 2022.

Year-to-date results can be found in the attached tables.

¹ Net income from continuing operations attributable to Merck & Co., Inc.

² Merck is providing certain 2022 and 2021 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non-GAAP pre-tax income metric. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to this release. Non-GAAP results for 2021 have been recast to conform to presentation changes implemented in 2022.

- 3 -

Cardiovascular pipeline highlights

Merck announced positive results from its pivotal Phase 3 STELLAR trial evaluating sotatercept, the company’s investigational activin receptor type IIA-Fc fusion protein, as an add-on to stable background therapy for the treatment of adults with pulmonary arterial hypertension. The trial met its primary efficacy outcome measure, demonstrating a statistically significant and clinically meaningful improvement in six-minute walk distance (6MWD) from baseline at 24 weeks, and eight out of nine secondary efficacy outcome measures, including the outcome measure of proportion of participants achieving multicomponent improvement [defined as improvement in 6MWD, improvement in N-terminal pro-B-type natriuretic peptide level, and either improvement in WHO Functional Class (FC) or maintenance of WHO FC II] and the outcome measure of time to death or the first occurrence of a clinical worsening event. The Cognitive/Emotional Impacts domain score of PAH-SYMPACT®, which was assessed as the ninth and final secondary outcome measure, did not achieve statistical significance. Results will be presented at an upcoming scientific congress.

Merck received a Fast Track designation from the U.S. Food and Drug Administration (FDA) for MK-2060, an investigational anticoagulant therapy for the reduction in risk of major thrombotic cardiovascular events in patients with end-stage renal disease.

Oncology program highlights

Merck announced clinical trial results for KEYTRUDA (pembrolizumab), the company’s anti-PD-1 therapy, and Lynparza (olaparib), an oral poly (ADP-ribose) PARP inhibitor being co-developed and co-commercialized with AstraZeneca, at the European Society for Medical Oncology Congress 2022, including:

Five-year overall survival (OS) data from the pivotal Phase 3 KEYNOTE-189 trial (KEYTRUDA plus pemetrexed and either cisplatin or carboplatin) in patients with metastatic nonsquamous non-small cell lung cancer (NSCLC) and the Phase 3 KEYNOTE-407 trial (KEYTRUDA plus carboplatin-paclitaxel or nab-paclitaxel) in patients with metastatic squamous NSCLC.

In collaboration with Seagen and Astellas, the first presentation of data from Cohort K of the Phase 1b/2 EV-103/KEYNOTE-869 trial evaluating Padcev (enfortumab vedotin-ejfv) in combination with KEYTRUDA as first-line treatment for patients with cisplatin-ineligible unresectable locally advanced or metastatic urothelial cancer.

- 4 -

Seven-year OS data from the Phase 3 SOLO-1 trial evaluating Lynparza as maintenance treatment in patients with advanced BRCA-mutated ovarian cancer, following first-line platinum-based chemotherapy, and final OS results from the Phase 3 PAOLA-1 trial evaluating Lynparza in combination with bevacizumab as maintenance treatment in patients with advanced ovarian cancer who were without evidence of disease after surgery or following response to platinum-based chemotherapy. The results of both trials were clinically meaningful in certain types of patients, but did not reach statistical significance.

Merck announced that KEYTRUDA received four new approvals in Japan; KEYTRUDA is now approved in Japan for 23 uses in 11 different types of cancer, plus microsatellite instability-high (MSI-H) and tumor mutational burden-high solid tumors.

Merck announced the following regulatory milestones for Lynparza:

Priority review granted by the FDA for a supplemental New Drug Application for Lynparza in combination with abiraterone and prednisone or prednisolone for patients with metastatic castration-resistant prostate cancer (mCRPC), based on results from the Phase 3 PROpel trial. The Prescription Drug User Fee Act (PDUFA) date is in the fourth quarter of 2022.

Approved in the European Union (EU) and Japan as adjuvant treatment for patients with germline BRCA-mutated, HER2-negative high-risk early breast cancer, based on results from the Phase 3 OlympiA trial.

Approved in China as first-line maintenance treatment with bevacizumab for patients with homologous recombination deficient-positive advanced ovarian cancer, based on results from the Phase 3 PAOLA-1 trial.

Merck provided updates on three Phase 3 trials: KEYNOTE-412, KEYNOTE-921 and LEAP-002.

Vaccines program highlights

Merck announced European Commission approval of an expanded indication for VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine) to include active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae (S. pneumoniae) in infants, children and adolescents from 6 weeks to less than 18 years of age.

Merck received approval from China’s National Medical Products Administration to expand the use of GARDASIL 9 [Human Papillomavirus (HPV) 9-valent Vaccine, Recombinant] for use in girls and women ages 9 to 45. The vaccine was previously approved for use in women ages 16 to 26.

- 5 -

Infectious diseases pipeline highlights

Merck will initiate a new Phase 3 clinical program with islatravir for the treatment of people with HIV-1 infection. These new Phase 3 studies will evaluate a once-daily oral combination of doravirine 100 mg and islatravir (DOR/ISL) 0.25 mg.

Merck and Gilead Sciences will resume the Phase 2 clinical trial evaluating an investigational oral once-weekly combination treatment regimen of islatravir and Gilead’s lenacapavir in adults with HIV-1 infection who are virologically suppressed.

Merck and Ridgeback Biotherapeutics (Ridgeback) provided an update on a preliminary analysis of the University of Oxford’s open label prospective real-world evidence study, PANORAMIC, of LAGEVRIO (molnupiravir).

Business development highlights

Merck and Moderna, Inc. (Moderna) announced that Merck has exercised its option to jointly develop and commercialize personalized cancer vaccine mRNA-4157/V940 pursuant to the terms of its existing collaboration and license agreement. mRNA-4157/V940 is currently being evaluated in combination with KEYTRUDA as adjuvant treatment for patients with high-risk melanoma in a Phase 2 clinical trial being conducted by Moderna.

Merck and Orna Therapeutics (Orna) announced a collaboration agreement to discover, develop and commercialize multiple programs, including vaccines and therapeutics in the areas of infectious diseases and oncology. This collaboration will combine Merck’s expertise in nucleic acid biology, clinical development, and manufacturing with Orna’s circular RNA technology.

Merck and Orion Corporation (Orion) formed a global development and commercialization agreement for Orion’s investigational candidate ODM-208/MK-5684 and other drugs targeting cytochrome P450 11A1 (CYP11A1), an enzyme important in steroid production. ODM-208/MK-5684 is an oral, non-steroidal inhibitor of CYP11A1 currently being evaluated in a Phase 2 clinical trial for the treatment of patients with mCRPC.

Merck acquired Vence, an innovator in virtual fencing for rotational grazing and livestock management, which complements Merck Animal Health’s broad portfolio of veterinary pharmaceuticals, vaccines and animal intelligence solutions.

- 6 -

Environmental, Social and Governance (ESG) highlights

Merck issued its 2021/2022 ESG Progress Report, highlighting the company’s performance and progress in ESG efforts across four main focus areas: Access to Health, Employees, Environmental Sustainability and Ethics & Values. These efforts come as part of a long-standing commitment to operating responsibly and creating value for patients and shareholders.

Merck launched the Alliance for Equity in Cancer Care, an initiative to advance equity in cancer care in the U.S. by helping patients living in underserved communities receive timely access to high-quality, culturally responsive care.

Merck was recognized on Fortune’s 2022 Change the World list for its work to make HPV vaccines broadly available in underserved countries through partnerships and manufacturing investments.

- 7 -

Third-quarter revenue performance

The following table reflects sales of the company’s top pharmaceutical products, as well as sales of Animal Health products.

	Third Quarter
$ in millions		2022		2021	Change		Change Ex-Exchange
Total Sales	$	14,959	$	13,154	14	%	18	%
Pharmaceutical		12,963		11,496	13	%	19	%
KEYTRUDA		5,426		4,534	20	%	26	%
GARDASIL / GARDASIL 9		2,294		1,993	15	%	20	%
JANUVIA / JANUMET		1,133		1,339	-15	%	-9	%
PROQUAD, M-M-R II and VARIVAX		668		661	1	%	3	%
LAGEVRIO		436		0	-		-
BRIDION		423		369	15	%	22	%
Lynparza*		284		246	16	%	23	%
ROTATEQ		256		227	12	%	16	%
Lenvima*		202		188	7	%	11	%
SIMPONI		173		203	-15	%	-2	%
Animal Health		1,371		1,417	-3	%	4	%
Livestock		829		864	-4	%	4	%
Companion Animals		542		553	-2	%	4	%
Other Revenues**		625		241	***		41	%

*Alliance revenue for this product represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.

**Other revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including

revenue-hedging activities.

***>100%

Pharmaceutical revenue

Third-quarter pharmaceutical sales increased 13% to $13.0 billion. Pharmaceutical sales growth in the third quarter was 9% excluding LAGEVRIO sales and 15% excluding LAGEVRIO sales and the impact of foreign exchange, primarily driven by oncology, vaccines and hospital acute care products. The COVID-19 pandemic unfavorably affected sales in the third quarter of 2021 by approximately $350 million, which favorably impacted the growth rate in the third quarter of 2022.

Growth in oncology was largely driven by higher sales of KEYTRUDA, which rose 20% to $5.4 billion in the quarter. Global sales growth of KEYTRUDA reflects continued strong momentum from metastatic indications including certain types of NSCLC, renal cell carcinoma, head and neck squamous cell carcinoma, triple-negative breast cancer (TNBC) and MSI-H cancers, and increased uptake across recent earlier-stage launches including certain types of neoadjuvant/adjuvant TNBC in the U.S.

- 8 -

Growth in vaccines was primarily driven by higher combined sales of GARDASIL (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and GARDASIL 9 vaccines to prevent certain cancers and other diseases caused by HPV. Third-quarter GARDASIL/GARDASIL 9 sales grew 15% to $2.3 billion, primarily driven by strong demand outside of the U.S., particularly in China, which also benefited from increased supply. Additionally, higher sales in the U.S. reflect public sector buying patterns. Growth in vaccines was partially offset by lower sales of PNEUMOVAX 23 (pneumococcal vaccine polyvalent), a vaccine to help prevent pneumococcal disease, which declined 53% to $131 million primarily reflecting lower U.S. demand as the market continues to shift toward newer adult pneumococcal conjugate vaccines.

Growth in hospital acute care reflects higher demand globally for BRIDION (sugammadex) injection 100 mg/mL, a medicine for the reversal of neuromuscular blockade induced by rocuronium bromide or vecuronium bromide in adults and pediatric patients ages 2 years and older undergoing surgery. Sales increased 15% to $423 million, primarily due to an increase in its share among neuromuscular blockade reversal agents and an increase in surgical procedures. Growth in hospital acute care also reflects higher sales of ZERBAXA (ceftolozane and tazobactam), a combination cephalosporin antibacterial and beta-lactamase inhibitor for the treatment of adults with certain bacterial infections. Sales of $43 million resulted from the phased resupply initiated in the fourth quarter of 2021, which has been completed in 2022.

Pharmaceutical sales growth was partially offset by lower combined sales of JANUVIA (sitagliptin) and JANUMET (sitagliptin and metformin HCI), which declined 15% to $1.1 billion, primarily reflecting lower demand and pricing in certain international markets as a result of generic competition, particularly in Europe, and lower demand in the U.S. The company lost market exclusivity for JANUVIA and JANUMET in China in July and in the EU in September, although JANUMET currently continues to have exclusivity in certain European markets.

Animal Health revenue

Animal Health sales totaled $1.4 billion for the third quarter of 2022, a decline of 3% compared with the third quarter of 2021. Excluding the unfavorable effect from foreign exchange, Animal Health sales grew 4% primarily reflecting higher pricing. Sales of livestock products also reflect higher demand for poultry products. Sales of companion animal products also reflect higher demand for the BRAVECTO (fluralaner) parasiticide line of products, partially offset by supply constraints for certain vaccines.

- 9 -

Third-quarter expense information

The tables below present selected expense information.

$ in millions Third Quarter 2022	GAAP			Acquisition- and Divestiture- Related Costs³			Restructuring Costs		(Income) Loss from Investments in Equity Securities			Non- GAAP²
Cost of sales	$	3,934		$	446		$	54	$	-		$	3,434
Selling, general and administrative		2,520			22			26		-			2,472
Research and development		4,399			902			1		-			3,496
Restructuring costs		94			-			94		-			-
Other (income) expense, net		429			(26	)		-		350			105

Third Quarter 2021
Cost of sales	$	3,450		$	346		$	48	$	-		$	3,056
Selling, general and administrative		2,336			61			5		-			2,270
Research and development		2,445			48			8		-			2,389
Restructuring costs		107			-			107		-			-
Other (income) expense, net		(450	)		(10	)		-		(684	)		244

GAAP expense, EPS and related information

Gross margin was 73.7% for the third quarter of 2022 compared to 73.8% for the third quarter of 2021. The decrease primarily reflects the impacts of higher revenue from third-party manufacturing arrangements and sales of LAGEVRIO, both of which have lower gross margins, as well as higher acquisition- and divestiture-related costs. The gross margin decline was largely offset by the favorable effects of product mix and foreign exchange.

Selling, general and administrative (SG&A) expenses were $2.5 billion in the third quarter of 2022, an increase of 8% compared to the third quarter of 2021. The increase primarily reflects higher administrative costs, including compensation and benefit costs, as well as higher promotional spending, partially offset by the favorable impact of foreign exchange.

Research and development (R&D) expenses were $4.4 billion in the third quarter of 2022 compared to $2.4 billion in the third quarter of 2021. The increase primarily reflects $887 million of intangible asset impairment charges related to the ArQule, Inc. acquisition, charges related to collaboration and licensing agreements with Moderna, Orna and Orion and higher clinical development spending.

³ Includes expenses for the amortization of intangible assets and purchase accounting adjustments to inventories recognized as a result of acquisitions, intangible asset impairment charges and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Also includes integration, transaction and certain other costs related to acquisitions and divestitures.

- 10 -

Other (income) expense, net, was $429 million of expense in the third quarter of 2022 compared to $450 million of income in the third quarter of 2021, primarily due to net unrealized losses from investments in equity securities in the third quarter of 2022, compared to net unrealized income from investments in equity securities in the third quarter of 2021. Other (income) expense, net, in the third quarter of 2022 also reflects lower pension costs compared to the third quarter of 2021.

The effective income tax rate was 9.2% for the third quarter of 2022 compared to 13.2% in the third quarter of 2021.

GAAP EPS was $1.28 for the third quarter of 2022 compared to $1.80 for the third quarter of 2021.

Non-GAAP expense, EPS and related information

Non-GAAP gross margin was 77.0% for the third quarter of 2022 compared to 76.8% for the third quarter of 2021. The increase in non-GAAP gross margin primarily reflects the favorable effects of product mix and foreign exchange, largely offset by the impacts of higher revenue from third-party manufacturing arrangements and sales of LAGEVRIO, both of which have lower gross margins.

Non-GAAP SG&A expenses were $2.5 billion in the third quarter of 2022, an increase of 9% compared to the third quarter of 2021. The increase primarily reflects higher administrative costs, including compensation and benefit costs, as well as higher promotional spending, partially offset by the favorable impact of foreign exchange.

Non-GAAP R&D expenses were $3.5 billion in the third quarter of 2022 compared to $2.4 billion in the third quarter of 2021. The increase primarily reflects charges related to collaboration and licensing agreements with Moderna, Orna and Orion and higher clinical development spending.

Non-GAAP other (income) expense, net, was $105 million of expense in the third quarter of 2022 compared to $244 million of expense in the third quarter of 2021, reflecting lower pension costs.

The non-GAAP effective income tax rate was 13.6% for the third quarter of 2022 compared to 12.8% in the third quarter of 2021.

- 11 -

Non-GAAP EPS was $1.85 for the third quarter of 2022 compared to $1.78 for the third quarter of 2021.

A reconciliation of GAAP to non-GAAP net income and EPS is provided in the table that follows.

	Third Quarter
$ in millions, except EPS amounts	2022			2021
EPS
GAAP EPS	$	1.28		$	1.80
Difference		0.57			(0.02	)
Non-GAAP EPS that excludes items listed below²	$	1.85		$	1.78

Net Income
GAAP net income¹	$	3,248		$	4,567
Difference		1,455			(42	)
Non-GAAP net income that excludes items listed below^1,2	$	4,703		$	4,525

Decrease (Increase) in Net Income Due to Excluded Items:
Acquisition- and divestiture-related costs³	$	1,344		$	445
Restructuring costs		175			168
Loss (income) from investments in equity securities		350			(684	)
Net decrease (increase) in income before taxes		1,869			(71	)
Estimated income tax (benefit) expense		(414	)		29
Decrease (increase) in net income	$	1,455		$	(42	)

Financial outlook

Beginning in 2022, Merck no longer excludes expenses for upfront and milestone payments related to collaboration and licensing agreements, or charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions from its non-GAAP results. Historically, the company excluded these charges to the extent they were considered by the company to be significant to the results of a particular period. These changes were made to align with views expressed by the U.S. Securities and Exchange Commission. Prior periods have been recast to reflect this change. For 2021, non-GAAP results have been recast to include $1.7 billion of incremental R&D expense, resulting in revised full-year 2021 EPS of $5.37.

Full-year 2022 GAAP and non-GAAP results include $690 million of incremental R&D expense, recorded in the third quarter of 2022, for collaboration and licensing agreements with Moderna, Orna and Orion which negatively impacts expected full-year EPS by $0.22.

As an on-going practice, the financial outlook will not include significant potential business development transactions.

- 12 -

Merck continues to experience strong global momentum across its key pillars of growth, particularly in oncology and vaccines. As a result, Merck is raising and narrowing its full-year outlook for sales and non-GAAP EPS, despite a negative impact from foreign exchange.

At mid-October 2022 exchange rates, Merck expects sales growth of 20% to 21% in 2022, with full-year sales estimated to be between $58.5 billion and $59.0 billion, including a negative impact from foreign exchange of approximately 4%, including a less than 1% incremental negative impact from prior sales outlook. Excluding LAGEVRIO, Merck expects sales growth of approximately 12% for full-year 2022.

Merck expects its full-year non-GAAP effective income tax rate to be approximately 14%.

Merck is lowering its expected full-year 2022 GAAP EPS to be between $5.68 and $5.73.

Merck is raising and narrowing its expected full-year 2022 non-GAAP EPS to be between $7.32 and $7.37, including a negative impact from foreign exchange of approximately 4% at mid-October exchange rates. Operational strength of approximately $0.20 is partially offset by the following negative impacts, which were not reflected previously in the outlook:

An option payment to Moderna of $250 million

A less than 1% incremental impact from foreign exchange

The non-GAAP range excludes acquisition- and divestiture-related costs and costs related to restructuring programs as well as income and losses from investments in equity securities.

The company is narrowing its expected full year sales range of LAGEVRIO to be between $5.2 billion and $5.4 billion. Merck shares profits equally with its partner, Ridgeback, which is reflected in cost of sales.

The following table summarizes the company’s full-year 2022 financial outlook.

	GAAP	Non-GAAP²
Sales	$58.5 to $59.0 billion	$58.5 to $59.0 billion*
Operating expenses	$22.5 to $22.9 billion	$21.3 to $21.7 billion
Effective tax rate	Approximately 11%	Approximately 14%
EPS**	$5.68 to $5.73	$7.32 to $7.37

*The company does not have any non-GAAP adjustments to sales.

**EPS outlook for 2022 assumes a share count (assuming dilution) of approximately 2.54 billion shares.

- 13 -

A reconciliation of anticipated full-year 2022 GAAP EPS to non-GAAP EPS and the items excluded from non-GAAP EPS are provided in the table below.

$ in millions, except EPS amounts		Full-Year 2022
GAAP EPS		$5.68 to $5.73
Difference		$1.64
Non-GAAP EPS that excludes items listed below²		$7.32 to $7.37

Acquisition- and divestiture-related costs		$3,400
Restructuring costs		600
(Income) loss from investments in equity securities		1,350
Net decrease (increase) in income before taxes		5,350
Estimated income tax (benefit) expense		(1,175)
Decrease (increase) in net income		$4,175

Earnings conference call

Investors, journalists and the general public may access a live audio webcast of the call Thursday, Oct. 27, at 8:00 a.m. ET via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available at www.merck.com.

Participants may join the call by dialing (877) 692-8955 (USA Toll-Free) or (243) 720-6979 (USA Caller Paid). If you are calling from other countries, visit this weblink. All dial-in participants can use the access code 9646315. Journalists who wish to ask questions are requested to contact a member of Merck’s Media Relations team.

About Merck

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.

- 14 -

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2021 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

###

Media Contacts:

Melissa Moody

Investor Contacts:

Peter Dannenbaum

(215) 407-3536

(908) 740-1037

Johanna Herrmann

(617) 216-6029

Steven Graziano

(908) 740-6582

- 15 -

MERCK & CO., INC.

CONSOLIDATED STATEMENT OF INCOME - GAAP

(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)

(UNAUDITED)

Table 1

On June 2, 2021, Merck completed the spin-off of products from its women’s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon & Co. (Organon). The historical results of the businesses that were contributed to Organon in the spin-off are excluded from sales and expenses and reflected as discontinued operations in the company’s Consolidated Statement of Income provided below.

	GAAP									GAAP
	3Q22			3Q21			% Change			Sep YTD 2022			Sep YTD 2021			% Change
Sales	$	14,959		$	13,154			14	%	$	45,453		$	35,183			29	%

Costs, Expenses and Other
Cost of sales		3,934			3,450			14	%		13,530			9,752			39	%
Selling, general and administrative		2,520			2,336			8	%		7,355			6,804			8	%
Research and development		4,399			2,445			80	%		9,773			9,177			6	%
Restructuring costs		94			107			-12	%		288			487			-41	%
Other (income) expense, net		429			(450	)		*			1,576			(1,007	)		*
Income from Continuing Operations Before Taxes		3,583			5,266			-32	%		12,931			9,970			30	%
Income Tax Provision		330			695						1,423			1,436
Net Income from Continuing Operations		3,253			4,571			-29	%		11,508			8,534			35	%
Less: Net Income Attributable to Noncontrolling Interests		5			4						6			9
Net Income from Continuing Operations Attributable to Merck & Co., Inc.		3,248			4,567			-29	%		11,502			8,525			35	%
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests		-			-			0	%		-			766			*
Net Income Attributable to Merck & Co., Inc.	$	3,248		$	4,567			-29	%	$	11,502		$	9,291			24	%

Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders:
Income from Continuing Operations	$	1.28		$	1.81			-29	%	$	4.55		$	3.37			35	%
Income from Discontinued Operations		-			-			0	%		-			0.30			*
Net Income	$	1.28		$	1.81			-29	%	$	4.55		$	3.67			24	%

Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders:
Income from Continuing Operations	$	1.28		$	1.80			-29	%	$	4.53		$	3.36			35	%
Income from Discontinued Operations		-			-			0	%		-			0.30			*
Net Income	$	1.28		$	1.80			-29	%	$	4.53		$	3.66			24	%

Average Shares Outstanding		2,533			2,530						2,531			2,531
Average Shares Outstanding Assuming Dilution		2,542			2,536						2,540			2,539
Tax Rate from Continuing Operations		9.2	%		13.2	%					11.0	%		14.4	%

* 100% or greater

- 16 -

MERCK & CO., INC.

THIRD QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2022 GAAP TO NON-GAAP RECONCILIATION - CONTINUING OPERATIONS

(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)

(UNAUDITED)

Table 2a

	GAAP			Acquisition and Divestiture-Related Costs ⁽¹⁾			Restructuring Costs ⁽²⁾			(Income) Loss from Investments in Equity Securities			Adjustment Subtotal			Non-GAAP
Third Quarter
Cost of sales	$	3,934			446			54						500		$	3,434
Selling, general and administrative		2,520			22			26						48			2,472
Research and development		4,399			902			1						903			3,496
Restructuring costs		94						94						94			-
Other (income) expense, net		429			(26	)					350			324			105
Income from Continuing Operations Before Taxes		3,583			(1,344	)		(175	)		(350	)		(1,869	)		5,452
Income Tax Provision (Benefit)		330			(302	)⁽³⁾		(35	)⁽³⁾		(77	)⁽³⁾		(414	)		744
Net Income from Continuing Operations		3,253			(1,042	)		(140	)		(273	)		(1,455	)		4,708
Net Income from Continuing Operations Attributable to Merck & Co., Inc.		3,248			(1,042	)		(140	)		(273	)		(1,455	)		4,703
Earnings per Common Share Assuming Dilution from Continuing Operations	$	1.28			(0.40	)		(0.06	)		(0.11	)		(0.57	)	$	1.85

Tax Rate		9.2	%														13.6	%

Sep YTD
Cost of sales	$	13,530			1,577			167						1,744		$	11,786
Selling, general and administrative		7,355			137			74						211			7,144
Research and development		9,773			936			30						966			8,807
Restructuring costs		288						288						288			-
Other (income) expense, net		1,576			(138	)					1,268			1,130			446
Income from Continuing Operations Before Taxes		12,931			(2,512	)		(559	)		(1,268	)		(4,339	)		17,270
Income Tax Provision (Benefit)		1,423			(587	)⁽³⁾		(97	)⁽³⁾		(281	)⁽³⁾		(965	)		2,388
Net Income from Continuing Operations		11,508			(1,925	)		(462	)		(987	)		(3,374	)		14,882
Net Income from Continuing Operations Attributable to Merck & Co., Inc.		11,502			(1,925	)		(462	)		(987	)		(3,374	)		14,876
Earnings per Common Share Assuming Dilution from Continuing Operations	$	4.53			(0.76	)		(0.18	)		(0.39	)		(1.33	)	$	5.86

Tax Rate		11.0	%														13.8	%

Only the line items that are affected by non-GAAP adjustments are shown.

Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.

⁽¹⁾Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses for the third quarter and nine month period primarily reflect $887 million of intangible asset impairment charges related to the ArQule, Inc. acquisition and expenses for the amortization of intangible assets. Amounts included in other (income) expense, net, for the third quarter and nine month period primarily reflect royalty income and a decrease in the estimated fair value measurement of liabilities for contingent consideration related to the prior termination of the Sanofi-Pasteur MSD joint venture.

⁽²⁾Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.

⁽³⁾ Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.

- 17 -

MERCK & CO., INC.

FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS

(AMOUNTS IN MILLIONS)

(UNAUDITED)

Table 3

	2022								2021																	3Q				September YTD
	1Q		2Q		3Q		Sep YTD		1Q			2Q			3Q			Sep YTD			4Q		Full Year			Nom %		Ex-Exch %		Nom %		Ex-Exch %
TOTAL SALES ⁽¹⁾	$	15,901	$	14,593	$	14,959	$	45,453	$	10,627		$	11,402		$	13,154		$	35,183		$	13,521	$	48,704			14		18		29	32
PHARMACEUTICAL		14,107		12,756		12,963		39,826		9,238			9,980			11,496			30,714			12,039		42,754			13		19		30	35
Oncology
Keytruda		4,809		5,252		5,426		15,487		3,899			4,176			4,534			12,609			4,577		17,186			20		26		23	28
Alliance Revenue – Lynparza ⁽²⁾		266		275		284		825		228			248			246			721			268		989			16		23		14	20
Alliance Revenue – Lenvima ⁽²⁾		227		231		202		660		130			181			188			498			206		704			7		11		33	36
Alliance Revenue – Reblozyl ⁽³⁾		52		33		39		124														17		17			*		*		*	*
Vaccines ⁽⁴⁾
Gardasil / Gardasil 9		1,460		1,674		2,294		5,428		917			1,234			1,993			4,144			1,528		5,673			15		20		31	35
ProQuad / M-M-R II / Varivax		470		578		668		1,716		449			516			661			1,626			509		2,135			1		3		6	7
RotaTeq		216		173		256		644		158			208			227			593			213		807			12		16		9	11
Pneumovax 23		173		153		131		457		171			152			277			600			292		893			-53		-50		-24	-21
Vaqta		36		35		64		134		34			56			48			138			41		179			33		34		-3	-2
Hospital Acute Care
Bridion		395		426		423		1,244		340			387			369			1,096			436		1,532			15		22		13	19
Prevymis		94		103		114		310		82			93			96			270			100		370			19		29		15	22
Dificid		52		66		77		196		27			34			54			115			60		175			42		42		70	70
Primaxin		58		64		63		185		65			60			70			194			65		259			-9		-5		-5	-3
Noxafil		57		60		62		180		67			66			64			197			62		259			-3		5		-9	-3
Invanz		52		46		50		148		57			48			53			157			45		202			-7		-1		-6	-1
Cancidas		53		42		43		138		57			54			56			168			45		212			-24		-19		-18	-15
Zerbaxa		30		46		43		120		(8	)		(1	)		(2	)		(11	)		10		(1	)		*		*		*	*
Cardiovascular
Alliance Revenue - Adempas/Verquvo ⁽⁵⁾		72		98		88		258		74			74			100			248			94		342			-12		-12		4	4
Adempas ⁽⁶⁾		61		63		57		181		55			74			59			188			63		252			-5		12		-4	8
Virology
Lagevrio		3,247		1,177		436		4,859														952		952			*		*		*	*
Isentress / Isentress HD		158		147		161		466		209			192			189			590			178		769			-15		-11		-21	-17
Neuroscience
Belsomra		69		69		62		199		79			78			81			238			80		318			-24		-12		-16	-7
Immunology
Simponi		186		181		173		540		214			202			203			619			206		825			-15		-2		-13	-2
Remicade		61		53		49		163		85			75			73			233			67		299			-33		-22		-30	-21
Diabetes ⁽⁷⁾
Januvia		779		756		717		2,252		809			784			852			2,445			878		3,324			-16		-10		-8	-3
Janumet		454		476		417		1,347		486			477			487			1,449			514		1,964			-14		-7		-7	-1
Other Pharmaceutical ⁽⁸⁾		520		479		564		1,565		554			512			518			1,589			533		2,118			9		17		-1	3

ANIMAL HEALTH		1,482		1,467		1,371		4,320		1,418			1,472			1,417			4,307			1,261		5,568			-3		4		-	6
Livestock		832		826		829		2,486		819			821			864			2,503			791		3,295			-4		4		-1	6
Companion Animals		650		641		542		1,834		599			651			553			1,804			470		2,273			-2		4		2	6

Other Revenues ⁽⁹⁾		312		370		625		1,307		(29	)		(50	)		241			162			221		382			159		41		*	*

* 200% or greater

Sum of quarterly amounts may not equal year-to-date amounts due to rounding.

⁽¹⁾ Only select products are shown.

⁽²⁾ Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.

⁽³⁾ Alliance Revenue represents royalties and a milestone payment.

⁽⁴⁾ Total Vaccines sales were $2,481 million, $2,709 million and $3,552 million in the first, second and third quarter of 2022, respectively, and $1,809 million, $2,293 million, $3,315 million and $2,715 million in the first, second, third and fourth quarter of 2021, respectively.

⁽⁵⁾ Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.

⁽⁶⁾ Net product sales in Merck's marketing territories.

⁽⁷⁾ Total Diabetes sales were $1,305 million, $1,300 million and $1,231 million in the first, second and third quarter of 2022, respectively, and $1,363 million, $1,330 million, $1,417 million and $1,475 million in the first, second, third and fourth quarter of 2021, respectively.

⁽⁸⁾ Includes Pharmaceutical products not individually shown above.

⁽⁹⁾ Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $114 million, $32 million and $10 million in the first, second and third quarter of 2022, respectively, and $56 million, $135 million and $27 million in the first, third and fourth quarter of 2021, respectively.

EX-99.2 3 tm2227726d1_ex99-2.htm EXHIBIT 99.2

Exhibit 99.2

MERCK & CO., INC.

CONSOLIDATED STATEMENT OF INCOME - GAAP

(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)

(UNAUDITED)

Table 1a

	2022												2021																		% Change
	1Q			2Q			3Q			Sep YTD			1Q			2Q			3Q			Sep YTD			4Q			Full Year			3Q			Sep YTD
Sales	$	15,901		$	14,593		$	14,959		$	45,453		$	10,627		$	11,402		$	13,154		$	35,183		$	13,521		$	48,704			14	%		29	%

Costs, Expenses and Other
Cost of sales		5,380			4,216			3,934			13,530			3,199			3,104			3,450			9,752			3,873			13,626			14	%		39	%
Selling, general and administrative		2,323			2,512			2,520			7,355			2,187			2,281			2,336			6,804			2,830			9,634			8	%		8	%
Research and development		2,576			2,798			4,399			9,773			2,412			4,321			2,445			9,177			3,068			12,245			80	%		6	%
Restructuring costs		53			142			94			288			297			82			107			487			174			661			-12	%		-41	%
Other (income) expense, net		708			438			429			1,576			(455	)		(103	)		(450	)		(1,007	)		(333	)		(1,341	)		*			*
Income from Continuing Operations Before Taxes		4,861			4,487			3,583			12,931			2,987			1,717			5,266			9,970			3,909			13,879			-32	%		30	%
Income Tax Provision		554			538			330			1,423			238			503			695			1,436			85			1,521
Net Income from Continuing Operations		4,307			3,949			3,253			11,508			2,749			1,214			4,571			8,534			3,824			12,358			-29	%		35	%
Less: Net (Loss) Income Attributable to Noncontrolling Interests		(3	)		5			5			6			4			1			4			9			4			13
Net Income from Continuing Operations Attributable to Merck & Co., Inc.		4,310			3,944			3,248			11,502			2,745			1,213			4,567			8,525			3,820			12,345			-29	%		35	%
Income (Loss) from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests		-			-			-			-			434			332			-			766			(62	)		704			0	%		*
Net Income Attributable to Merck & Co., Inc.	$	4,310		$	3,944		$	3,248		$	11,502		$	3,179		$	1,545		$	4,567		$	9,291		$	3,758		$	13,049			-29	%		24	%

Basic Earnings (Loss) per Common Share Attributable to Merck & Co., Inc. Common Shareholders:
Income from Continuing Operations	$	1.70		$	1.56		$	1.28		$	4.55		$	1.08		$	0.48		$	1.81		$	3.37		$	1.51		$	4.88			-29	%		35	%
Income (Loss) from Discontinued Operations		-			-			-			-			0.17			0.13			-			0.30			(0.02	)		0.28			0	%		*
Net Income	$	1.70		$	1.56		$	1.28		$	4.55		$	1.26		$	0.61		$	1.81		$	3.67		$	1.49		$	5.16			-29	%		24	%

Earnings (Loss) per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders:
Income from Continuing Operations	$	1.70		$	1.55		$	1.28		$	4.53		$	1.08		$	0.48		$	1.80		$	3.36		$	1.51		$	4.86			-29	%		35	%
Income (Loss) from Discontinued Operations		-			-			-			-			0.17			0.13			-			0.30			(0.02	)		0.28			0	%		*
Net Income	$	1.70		$	1.55		$	1.28		$	4.53		$	1.25		$	0.61		$	1.80		$	3.66		$	1.48		$	5.14			-29	%		24	%

Average Shares Outstanding		2,528			2,531			2,533			2,531			2,531			2,533			2,530			2,531			2,527			2,530
Average Shares Outstanding Assuming Dilution		2,537			2,540			2,542			2,540			2,541			2,540			2,536			2,539			2,535			2,538
Tax Rate from Continuing Operations		11.4	%		12.0	%		9.2	%		11.0	%		8.0	%		29.3	%		13.2	%		14.4	%		2.2	%		11.0	%

* 100% or greater

Sum of quarterly amounts may not equal year-to-date amounts due to rounding.

MERCK & CO., INC.

THIRD QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2021 GAAP TO NON-GAAP RECONCILIATION - CONTINUING OPERATIONS

(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)

(UNAUDITED)

Table 2b

In 2022, the company changed the treatment of certain items for purposes of its non-GAAP reporting. Historically, Merck’s non-GAAP results excluded expenses for upfront and milestone payments related to collaborations and licensing agreements, as well as charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions, to the extent the charges were considered by the company to be significant to the results of a particular period (as well as any related adjustments recorded in a subsequent period). Beginning in 2022, Merck’s non-GAAP results no longer exclude charges related to these items. Results for 2021 have been recast to conform to the new presentation.

The table below reflects a reconciliation of GAAP to non-GAAP financial information on a continuing operations basis. As Organon results are reflected within discontinued operations, they are excluded from the financial information provided below.

	GAAP			Acquisition and Divestiture- Related Costs ⁽¹⁾			Restructuring Costs ⁽²⁾			(Income) Loss from Investments in Equity Securities			Certain Other Items			Adjustment Subtotal			Non-GAAP
Third Quarter
Cost of sales	$	3,450			346			48									394		$	3,056
Selling, general and administrative		2,336			61			5									66			2,270
Research and development		2,445			48			8									56			2,389
Restructuring costs		107						107									107			-
Other (income) expense, net		(450	)		(10	)					(684	)					(694	)		244
Income from Continuing Operations Before Taxes		5,266			(445	)		(168	)		684						71			5,195
Income Tax Provision (Benefit)		695			(96	)⁽⁴⁾		(26	)⁽⁴⁾		151	⁽⁴⁾					29			666
Net Income from Continuing Operations		4,571			(349	)		(142	)		533						42			4,529
Net Income from Continuing Operations Attributable to Merck & Co., Inc.		4,567			(349	)		(142	)		533						42			4,525
Earnings per Common Share Assuming Dilution from Continuing Operations	$	1.80			(0.13	)		(0.06	)		0.21						0.02		$	1.78

Tax Rate		13.2	%																	12.8	%

Sep YTD
Cost of sales	$	9,752			1,188			113						225	⁽³⁾		1,526		$	8,226
Selling, general and administrative		6,804			96			9									105			6,699
Research and development		9,177			82			21									103			9,074
Restructuring costs		487						487									487			-
Other (income) expense, net		(1,007	)		79						(1,503	)					(1,424	)		417
Income from Continuing Operations Before Taxes		9,970			(1,445	)		(630	)		1,503			(225	)		(797	)		10,767
Income Tax Provision (Benefit)		1,436			(283	)⁽⁴⁾		(82	)⁽⁴⁾		331	⁽⁴⁾		(257	)⁽⁴⁾		(291	)		1,727
Net Income from Continuing Operations		8,534			(1,162	)		(548	)		1,172			32			(506	)		9,040
Net Income from Continuing Operations Attributable to Merck & Co., Inc.		8,525			(1,162	)		(548	)		1,172			32			(506	)		9,031
Earnings per Common Share Assuming Dilution from Continuing Operations	$	3.36			(0.46	)		(0.22	)		0.46			0.02			(0.20	)	$	3.56

Tax Rate		14.4	%																	16.0	%

Only the line items that are affected by non-GAAP adjustments are shown.

⁽¹⁾Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions and divestitures. Amounts included in research and development expenses primarily reflect expenses for the amortization of intangible assets. Amounts included in other (income) expense, net, for the third quarter and nine month period primarily reflect an increase in the estimated fair value measurement of liabilities for contingent consideration related to the prior termination of the Sanofi-Pasteur MSD joint venture. Additionally, the nine month period also includes a loss on a forward exchange contract entered into in conjunction with the Organon spin-off. Amount included in other (income) expense, net, for the nine month period was partially offset by royalty income related to the prior termination of the Sanofi-Pasteur MSD joint venture.

⁽³⁾ Represents charges for the discontinuation of COVID-19 development programs.

⁽⁴⁾ Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Certain other items for the nine month period also includes a $207 million net tax benefit related to the settlement of certain federal income tax matters.

MERCK & CO., INC.

FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS

THIRD QUARTER 2022

(AMOUNTS IN MILLIONS)

(UNAUDITED)

Table 3a

	Global							U.S.							International
	3Q 2022		3Q 2021			% Change		3Q 2022		3Q 2021			% Change		3Q 2022		3Q 2021			% Change
TOTAL SALES ⁽¹⁾	$	14,959	$	13,154			14	$	7,322	$	6,276			17	$	7,637	$	6,878			11
PHARMACEUTICAL		12,963		11,496			13		6,620		5,670			17		6,343		5,826			9
Oncology
Keytruda		5,426		4,534			20		3,331		2,580			29		2,095		1,954			7
Alliance Revenue - Lynparza ⁽²⁾		284		246			16		144		129			12		140		117			20
Alliance Revenue - Lenvima ⁽²⁾		202		188			7		142		114			25		60		74			-19
Alliance Revenue - Reblozyl ⁽³⁾		39					*		32					*		7					*
Vaccines ⁽⁴⁾
Gardasil / Gardasil 9		2,294		1,993			15		957		839			14		1,337		1,154			16
ProQuad / M-M-R II / Varivax		668		661			1		532		537			-1		136		125			9
RotaTeq		256		227			12		154		135			13		102		92			11
Pneumovax 23		131		277			-53		68		181			-62		63		97			-35
Vaqta		64		48			33		27		32			-16		36		16			134
Hospital Acute Care
Bridion		423		369			15		233		181			29		190		188			1
Prevymis		114		96			19		49		39			26		64		57			14
Dificid		77		54			42		72		52			37		6		2			146
Primaxin		63		70			-9							-57		63		69			-9
Noxafil		62		64			-3		13		19			-30		49		45			8
Invanz		50		53			-7		2		(2	)		-174		48		55			-14
Zerbaxa		43		(2	)		*		24		(1	)		*		19		(1	)		*
Cancidas		43		56			-24		1		1			81		42		56			-25
Cardiovascular
Alliance Revenue - Adempas/Verquvo ⁽⁵⁾		88		100			-12		85		73			17		3		27			-90
Adempas ⁽⁶⁾		57		59			-5									57		59			-5
Virology
Lagevrio		436					*							-		436					*
Isentress / Isentress HD		161		189			-15		68		77			-12		93		112			-17
Neuroscience
Belsomra		62		81			-24		20		23			-13		42		58			-28
Immunology
Simponi		173		203			-15									173		203			-15
Remicade		49		73			-33									49		73			-33
Diabetes ⁽⁷⁾
Januvia		717		852			-16		332		365			-9		385		487			-21
Janumet		417		487			-14		90		86			4		327		401			-18
Other Pharmaceutical ⁽⁸⁾		564		518			9		244		210			16		321		306			5

ANIMAL HEALTH		1,371		1,417			-3		475		467			2		896		951			-6
Livestock		829		864			-4		186		190			-2		643		675			-5
Companion Animals		542		553			-2		289		277			4		253		276			-8

Other Revenues ⁽⁹⁾		625		241			159		227		139			63		398		101			*

* 200% or greater

Sum of U.S. plus international may not equal global due to rounding.

⁽¹⁾ Only select products are shown.

⁽²⁾ Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.

⁽³⁾ Alliance Revenue represents royalties.

⁽⁴⁾ Total Vaccines sales were $3,552 million in the third quarter of 2022 and $3,315 million in the third quarter of 2021.

⁽⁵⁾ Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.

⁽⁶⁾ Net product sales in Merck's marketing territories.

⁽⁷⁾ Total Diabetes sales were $1,231 million in the third quarter of 2022 and $1,417 million in the third quarter of 2021.

⁽⁸⁾ Includes Pharmaceutical products not individually shown above.

⁽⁹⁾ Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $10 million in the third quarter of 2022 and $135 million in the third quarter of 2021.

MERCK & CO., INC.

FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS

SEPTEMBER YEAR-TO-DATE 2022

(AMOUNTS IN MILLIONS)

(UNAUDITED)

Table 3b

	Global							U.S.							International
	September YTD 2022		September YTD 2021			% Change		September YTD 2022		September YTD 2021			% Change		September YTD 2022		September YTD 2021			% Change
TOTAL SALES ⁽¹⁾	$	45,453	$	35,183			29	$	20,927	$	16,166			29	$	24,526	$	19,017			29
PHARMACEUTICAL		39,826		30,714			30		19,119		14,611			31		20,707		16,103			29
Oncology
Keytruda		15,487		12,609			23		9,307		7,108			31		6,180		5,501			12
Alliance Revenue - Lynparza ⁽²⁾		825		721			14		427		371			15		397		350			14
Alliance Revenue - Lenvima ⁽²⁾		660		498			33		426		287			48		235		211			11
Alliance Revenue - Reblozyl ⁽³⁾		124					*		87					*		37					*
Vaccines ⁽⁴⁾
Gardasil / Gardasil 9		5,428		4,144			31		1,803		1,605			12		3,624		2,539			43
ProQuad / M-M-R II / Varivax		1,716		1,626			6		1,337		1,255			6		379		371			2
RotaTeq		644		593			9		427		364			17		218		229			-5
Pneumovax 23		457		600			-24		280		354			-21		177		247			-28
Vaqta		134		138			-3		72		80			-9		62		58			6
Hospital Acute Care
Bridion		1,244		1,096			13		665		545			22		579		551			5
Prevymis		310		270			15		136		111			23		174		159			9
Dificid		196		115			70		184		108			70		12		7			75
Primaxin		185		194			-5		1					87		185		194			-5
Noxafil		180		197			-9		39		48			-20		141		149			-5
Invanz		148		157			-6		4		(2	)		*		144		159			-10
Cancidas		138		168			-18		5		4			27		133		164			-19
Zerbaxa		120		(11	)		*		64		(5	)		*		55		(6	)		*
Cardiovascular
Alliance Revenue - Adempas/Verquvo ⁽⁵⁾		258		248			4		244		222			10		14		26			-47
Adempas ⁽⁶⁾		181		188			-4									181		188			-4
Virology
Lagevrio		4,859					*		1,523					*		3,336					*
Isentress / Isentress HD		466		590			-21		196		222			-12		270		368			-27
Neuroscience
Belsomra		199		238			-16		60		56			7		139		183			-24
Immunology
Simponi		540		619			-13									540		619			-13
Remicade		163		233			-30									163		233			-30
Diabetes ⁽⁷⁾
Januvia		2,252		2,445			-8		958		997			-4		1,294		1,448			-11
Janumet		1,347		1,449			-7		258		244			6		1,089		1,205			-10
Other Pharmaceutical ⁽⁸⁾		1,565		1,589			-1		616		637			-3		949		950			-

ANIMAL HEALTH		4,320		4,307			-		1,425		1,363			5		2,894		2,944			-2
Livestock		2,486		2,503			-1		521		508			3		1,965		1,996			-2
Companion Animals		1,834		1,804			2		904		855			6		929		948			-2

Other Revenues ⁽⁹⁾		1,307		162			*		383		192			99		925		(30	)		*

* 200% or greater

Sum of U.S. plus international may not equal global due to rounding.

⁽¹⁾ Only select products are shown.

⁽²⁾ Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.

⁽³⁾ Alliance Revenue represents royalties and a milestone payment.

⁽⁴⁾ Total Vaccines sales were $8,743 million and $7,417 million on a global basis for September YTD 2022 and 2021, respectively.

⁽⁵⁾ Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.

⁽⁶⁾ Net product sales in Merck's marketing territories.

⁽⁷⁾ Total Diabetes sales were $3,836 million and $4,110 million on a global basis for September YTD 2022 and 2021, respectively.

⁽⁸⁾ Includes Pharmaceutical products not individually shown above.

⁽⁹⁾ Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $156 million and $191 million on a global basis for September YTD 2022 and 2021, respectively.

MERCK & CO., INC.

PHARMACEUTICAL GEOGRAPHIC SALES - CONTINUING OPERATIONS

(AMOUNTS IN MILLIONS)

(UNAUDITED)

Table 3c

	2022												2021																		% Change
	1Q			2Q			3Q			Sep YTD			1Q			2Q			3Q			Sep YTD			4Q			Full Year			3Q		Sep YTD
TOTAL PHARMACEUTICAL	$	14,107		$	12,756		$	12,963		$	39,826		$	9,238		$	9,980		$	11,496		$	30,714		$	12,039		$	42,754			13		30

United States		6,773			5,726			6,620			19,119			4,294			4,647			5,670			14,611			5,790			20,401			17		31
% Pharmaceutical Sales		48.0	%		44.9	%		51.1	%		48.0	%		46.5	%		46.6	%		49.3	%		47.6	%		48.1	%		47.7	%
Europe ⁽¹⁾		3,309			2,677			2,427			8,412			2,276			2,404			2,445			7,124			2,655			9,780			-1		18
% Pharmaceutical Sales		23.5	%		21.0	%		18.7	%		21.1	%		24.6	%		24.1	%		21.3	%		23.2	%		22.1	%		22.9	%
China		1,113			1,355			1,419			3,887			688			944			1,278			2,910			1,352			4,262			11		34
% Pharmaceutical Sales		7.9	%		10.6	%		10.9	%		9.8	%		7.4	%		9.5	%		11.1	%		9.5	%		11.2	%		10.0	%
Japan		965			1,092			653			2,710			607			637			614			1,858			771			2,629			6		46
% Pharmaceutical Sales		6.8	%		8.6	%		5.0	%		6.8	%		6.6	%		6.4	%		5.3	%		6.0	%		6.4	%		6.1	%
Asia Pacific (other than China and Japan)		786			854			702			2,342			437			442			450			1,329			488			1,817			56		76
% Pharmaceutical Sales		5.6	%		6.7	%		5.4	%		5.9	%		4.7	%		4.4	%		3.9	%		4.3	%		4.1	%		4.2	%
Latin America		435			453			511			1,399			353			379			434			1,166			421			1,587			18		20
% Pharmaceutical Sales		3.1	%		3.6	%		3.9	%		3.5	%		3.8	%		3.8	%		3.8	%		3.8	%		3.5	%		3.7	%
Eastern Europe/Middle East/Africa		450			339			360			1,149			357			318			362			1,037			278			1,315			-1		11
% Pharmaceutical Sales		3.2	%		2.7	%		2.8	%		2.9	%		3.9	%		3.2	%		3.1	%		3.4	%		2.3	%		3.1	%
Canada		189			166			166			521			160			157			164			482			167			650			1		8
% Pharmaceutical Sales		1.3	%		1.3	%		1.3	%		1.3	%		1.7	%		1.6	%		1.4	%		1.6	%		1.4	%		1.5	%
Other		87			94			105			287			66			52			79			197			117			313			33		46
% Pharmaceutical Sales		0.6	%		0.6	%		0.9	%		0.7	%		0.8	%		0.4	%		0.8	%		0.6	%		0.9	%		0.8	%

Sum of quarterly amounts may not equal year-to-date amounts due to rounding.

⁽¹⁾ Europe represents all European Union countries, the European Union accession markets and the United Kingdom.

MERCK & CO., INC.

OTHER (INCOME) EXPENSE, NET - GAAP

(AMOUNTS IN MILLIONS)

(UNAUDITED)

Table 4

OTHER (INCOME) EXPENSE, NET

	3Q22			3Q21			Sep YTD 2022			Sep YTD 2021
Interest income	$	(40	)	$	(7	)	$	(62	)	$	(27	)
Interest expense		244			196			727			597
Exchange losses		96			46			220			202
Loss (income) from investments in equity securities, net ⁽¹⁾		371			(683	)		1,361			(1,535	)
Net periodic defined benefit plan (credit) cost other than service cost		(60	)		40			(208	)		(159	)
Other, net		(182	)		(42	)		(462	)		(85	)
Total	$	429		$	(450	)	$	1,576		$	(1,007	)

⁽¹⁾Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag.

EX-99.3 4 tm2227726d1_ex99-3.htm EXHIBIT 99.3

Exhibit 99.3

News Release

Media Contact:	Johanna Herrmann	Investor Contact:	Peter Dannenbaum
	(617) 216-6029		(908) 740-1037

Robert M. Davis to Succeed Kenneth C. Frazier as Chairman of Merck

Frazier to Retire After 30 years at Merck; Board of Directors Elects Davis as Company Chairman

RAHWAY, N.J., October 26, 2022 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Merck board of directors has unanimously elected Robert M. Davis to serve as chairman of the board, effective Dec. 1, 2022. He will succeed Kenneth C. Frazier, who plans to retire on Nov. 30, 2022, after a long-tenured career at Merck that began in 1992. Frazier led the company for 10 years as president and chief executive officer, from 2011 through 2021. He has served as a Merck director since Jan. 2011 and chairman of its board of directors since Dec. 2011.

Davis, who currently serves as president and chief executive officer, became Merck’s president in April 2021 and was named Merck’s chief executive officer and a member of its board in July 2021.

Speaking on behalf of Merck’s board of directors, Thomas H. Glocer, independent lead director, stated, “I want to thank Ken for his principled leadership, extraordinary integrity, and unwavering commitment to delivering on Merck’s purpose of saving and improving lives around the world.”

“For decades, Ken has embodied Merck’s core principles and values, anchored by a singular focus on creating meaningful value for our patients, employees, communities and shareholders,” Glocer added. “Ken is a once-in-a-generation leader, and his positive impact on our company and patients everywhere will reverberate for decades.”

Glocer continued, “Rob Davis has shown himself to be an innovative leader with a deep understanding of Merck and our industry. We look forward to working with him as our new chairman and to his continued contributions.”

Frazier said, “Merck is powered by the talent, passion and commitment of many thousands of people around the world who are united by a common goal: harnessing the power of science to solve the world’s most pressing health challenges. It has been a distinct pleasure and privilege to be a part of the Merck team, and I will be forever grateful to my Merck colleagues for their dedicated efforts that have led to the company’s many important achievements.”

“I am also grateful to the Merck board of directors for their expertise and support through the years. With Rob Davis as their new chairman, I am confident that the board will continue to help guide the company in a manner that will allow it to succeed competitively and remain committed to its mission,” Frazier added.

“On behalf of Merck management and our colleagues around the world, I want to express our deepest appreciation for Ken’s innumerable contributions and indelible impact on our company and global health,” said Davis. “During his tenure, Ken led with conviction, advocated for patients and created meaningful value for our stakeholders. He has been an exemplar of purpose-driven leadership, vision and courage. I am honored to lead Merck as chairman and chief executive officer as we continue to build on his profound legacy.”

About Robert M. Davis

Rob Davis is chief executive officer and president of Merck.

Previously, Rob served as Merck’s president, responsible for the company’s operating divisions — Human Health, Animal Health, Manufacturing and Merck Research Laboratories. Prior to that, he was executive vice president, Global Services, and the company’s chief financial officer.

Rob joined the company as chief financial officer in 2014 with additional responsibility for real estate operations, corporate strategy and business development. In 2016, his role was expanded to include responsibility for information technology and procurement, forming Global Services. He became president in April 2021 and CEO and a member of the board of directors on July 1, 2021.

Prior to joining Merck, Rob was corporate vice president and president of Baxter’s Medical Products business. During his tenure at Baxter, he held several other positions, including president of Baxter’s Renal business, chief financial officer and treasurer. Before joining Baxter in 2004, Rob held numerous positions of increasing responsibility over 14 years at Eli Lilly and Company.

Rob serves on the board of directors for Duke Energy Corporation and is chair of its finance and risk management committee and a member of the corporate governance committee. In addition, Rob is a board member of Project Hope, a non-profit organization focused on empowering health care workers to deliver expert care when and where it is needed most.

Rob received his J.D. from Northwestern University School of Law, his M.B.A. from Northwestern University’s Kellogg Graduate School of Management and his bachelor’s degree in finance from Miami University.

About Kenneth C. Frazier

Kenneth C. Frazier has served as executive chairman of Merck’s board of directors since July 2021, following his retirement from a decade-long tenure as Merck’s president and chief executive officer.

Under Ken’s leadership, Merck delivered innovative life-saving medicines and vaccines as well as long-term and sustainable value to its multiple stakeholders. Ken substantially increased Merck’s investment in research, including early research, while refocusing the organization on the launch and growth of key products that provide far-reaching benefits to society. He also led the formation of philanthropic and humanitarian initiatives that build on Merck’s 130-year legacy.

Ken joined the company in 1992 and held positions of increasing responsibility, including general counsel, before becoming president and chief executive officer in 2011. Prior to joining Merck, Ken was a Partner with the Philadelphia law firm of Drinker Biddle & Reath. Ken’s contributions, especially in the legal, business, and humanitarian fields, have been widely recognized. He sits on the boards of Weill Cornell Medicine, Eikon Therapeutics, the National Constitution Center and Cornerstone Christian Academy in Philadelphia, PA. He is Co-Founder and Co-Chair of OneTen, a coalition of leading organizations committed to upskilling, hiring, and promoting one million Black Americans into family-sustaining jobs. OneTen is committed to facilitating a meaningful, measurable, and lasting impact on racial and economic justice. Ken is also Chairman, Health Assurance Initiatives, at the venture capital firm, General Catalyst, where he advises on investments and partnerships and provides mentorship to founders building companies that are well positioned to transform the healthcare industry through collaborative and responsible innovation. He also is a member of the American Academy of Arts and Sciences, the American Philosophical Society, The Business Council, the Council of the American Law Institute, the American Bar Association, and a Fellow of the College of Physicians of Philadelphia. Additionally, Ken is Co-Chair of the Legal Services Corporation’s Leaders Council.

As a strong advocate for social justice and economic inclusion, Ken is the recipient of numerous awards and honors, including the Anti-Defamation League Courage Against Hate Award, the Botwinick Prize in Business Ethics from Columbia Business School, the Legend in Leadership Award from the Yale School of Management, the NAACP Legal Defense and Educational Fund National Equal Justice Award, and the National Minority Quality Forum’s Lifetime Achievement Award. In 2018, Ken received the Harvard Law School Association Award, the highest honor given by the prestigious association, in recognition of his extraordinary service to the legal profession, Harvard Law School, and the public. In that same year, Ken was named one of the World’s Greatest Leaders by Fortune magazine and was also named one of TIME’s 100 Most Influential People and again made that list in 2021. In 2019, he became the first recipient of the Forbes Lifetime Achievement Award for Healthcare. In 2021, Columbia Business School honored him with the Deming Cup for Operational Excellence, and his peers named Ken Chief Executive magazine’s CEO of the Year.

Ken received his bachelor’s degree from The Pennsylvania State University and holds a J.D. from Harvard Law School.

About Merck

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

EX-101.SCH 5 mrk-20221026.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 6 mrk-20221026_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 7 mrk-20221026_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Common Stock 0.500% Notes due 2024 1.875% Notes due 2026 2.500% Notes due 2034 1.375% Notes due 2036 Statement [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 8 mrk-20221026_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 9 tm2225765d1_ex99-1img001.jpg GRAPHIC begin 644 tm2225765d1_ex99-1img001.jpg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end GRAPHIC 10 tm2227726d1_ex99-3imag007.jpg GRAPHIC begin 644 tm2227726d1_ex99-3imag007.jpg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end XML 11 R1.htm IDEA: XBRL DOCUMENT

Cover	Oct. 26, 2022
Document Information [Line Items]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Oct. 26, 2022
Entity File Number	1-6571
Entity Registrant Name	Merck & Co., Inc.
Entity Central Index Key	0000310158
Entity Tax Identification Number	22-1918501
Entity Incorporation, State or Country Code	NJ
Entity Address, Address Line One	126 East Lincoln Avenue
Entity Address, City or Town	Rahway
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07065
City Area Code	908
Local Phone Number	740-4000
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false
Common Stock
Document Information [Line Items]
Title of 12(b) Security	Common Stock ($0.50 par value)
Trading Symbol	MRK
Security Exchange Name	NYSE
0.500% Notes due 2024
Document Information [Line Items]
Title of 12(b) Security	0.500% Notes due 2024
Trading Symbol	MRK 24
Security Exchange Name	NYSE
1.875% Notes due 2026
Document Information [Line Items]
Title of 12(b) Security	1.875% Notes due 2026
Trading Symbol	MRK/26
Security Exchange Name	NYSE
2.500% Notes due 2034
Document Information [Line Items]
Title of 12(b) Security	2.500% Notes due 2034
Trading Symbol	MRK/34
Security Exchange Name	NYSE
1.375% Notes due 2036
Document Information [Line Items]
Title of 12(b) Security	1.375% Notes due 2036
Trading Symbol	MRK 36A
Security Exchange Name	NYSE

XML 12 tm2227726d1_8k_htm.xml IDEA: XBRL DOCUMENT 0000310158 2022-10-26 2022-10-26 0000310158 us-gaap:CommonStockMember 2022-10-26 2022-10-26 0000310158 mrk:Sec0.500NotesDue2024Member 2022-10-26 2022-10-26 0000310158 mrk:Sec1.875NotesDue2026Member 2022-10-26 2022-10-26 0000310158 mrk:Sec2.500NotesDue2034Member 2022-10-26 2022-10-26 0000310158 mrk:Sec1.375NotesDue2036Member 2022-10-26 2022-10-26 iso4217:USD shares iso4217:USD shares 0000310158 false 8-K 2022-10-26 Merck & Co., Inc. NJ 1-6571 22-1918501 126 East Lincoln Avenue Rahway NJ 07065 908 740-4000 false false false false false Common Stock ($0.50 par value) MRK NYSE 0.500% Notes due 2024 MRK 24 NYSE 1.875% Notes due 2026 MRK/26 NYSE 2.500% Notes due 2034 MRK/34 NYSE 1.375% Notes due 2036 MRK 36A NYSE EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( ,0T6U4'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #$-%M5/X&%*.\ K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M:L,P#(=?9?B>R$G8'TSJ2\M.&PQ6V-C-V&IK&L?&UDCZ]DN\-F5L#["CI9\_ M?0*U.@CM([Y$'S"2Q70SNJY/0H<5.Q % 9#T 9U*Y93HI^;.1Z=H>L8]!*6/ M:H]0M[!] M(M5KG'XE*^@4<,4ND]^:]6;[R&3-Z[JH>%'?;RLNF@?!;S]FUQ]^5V'GC=W9 M?VQ\$90M_+H+^0502P,$% @ Q#1;59E&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" #$-%M51<.@>8,% !0'@ & 'AL+W=OS$.OGY7NDHDSL18 MD:),4ZX>3D4B%\S;5YHS,\ROE,3(3^/1\KV.O4*E&W']4_5B'9_).J*..!BGS1B=<#3M= M#F,;AGT)=9NPWAYA'F-/AW> H,9@-0:K]/P->A]D6$*O-3G/EC/-=.SOSW 4 M.=>P38KX%]3-T"7S_D MH@D.'S[8_X1 !#5$@*J< $%447Q,^*R) A\_Y4DA$(YNS='=KAACH6(9D5$6 M$9B-C77!E>IYY9I8O1JMAPJ.,AWK!_(Q3@2Y+-.;YLF.:]#]7K=/$9A^#=/? M!N9*S.)"*PX%N^1I8Y5PG0NAPEORAJ?Y>W(FVWNP:L(VPC>H^0;;\)U!*Q5/ M0#42]^23>&@BQ)4\>/G4H]T!@G508QUL@W7-[\EY!&SQ- Z7#K&YH[@B8_OT M@ ZZ'M95ZED/];8!A"Y(E4M5L>V1B88E0*2"%I504*BKC!J;[5"__ V#7#-Z MN@WD212!&Q9[CQND,MDO63,9+DE9CXQXH8T&!%%&3NY$5F*.0FT@4-2^O\$] M,WM0S&NYR!I1<;DK/E_P!XS,.C_%O?LY6=WGL9)W4(CF2N*:>(]M'E#>;)Q^NZ/6]7A=CLQE!<6NO&G@"5XZ;47"! P\S$VH3@>)V_EF& M4)/Q7&98)#A$^H&W'X#)840V%BCNYU]5K+7(H#!I6F8K7,7)8R. XHX]5F(_A/((6%_+ZRZX]!&*?)E. M-_0/UW.1,6O^#+?G;\C.BZ($,A>@0]8):(V?;67\HU2HF>GG+Z"@YV:RY3QK MS':'H!-M[:H?=V4SX2'&)UJ&MXT@N[C$9];IF;^#7R6HT[^4V48 PPW[.M9P MJ2NGA+*W-^_(1(0EN$MSFW&E97-^(/"J&D3>_N2UNQ[)N2)W/"G%.PS8Y@+# M;?U:\B,;3<8A<'&%_99B-A<8;NF/I2*C^W#.LYG8>'7N$+K\>F$01&T=J=HAVDB+^+%/%MBOBOEB(.I2VZ])31!H?_O<'A$(#5T<%9 M;';XKY4=#B'7ZK#9X>/9P;YU);\Q.W"=E\XTFQW^#K+#WT5V^#8[_%?+#H?2 M%EUZ>F?89D?PO=GA$#"K V>QV1&\5G8XA!RK([#9$;BRPW_N2GYC=N Z+YQI M@PB.X*UAQ*OEAT.I2VZ])319D?PO=GA$#!75G[O!(.QX1&\5G@X MA#8MC\[:\T'SK/6"FSL!!4G$%'2\=A_.52T?7RYWM,RK1X8W4FN95IMSP2.A MS 'P^51"2U8[YBED_1!Y^!]02P,$% @ Q#1;59^@&_"Q @ X@P T M !X;"]S='EL97,N>&ULW5=M:]LP$/XK0C]@;F)JXI$8MD!AL(U"\V%?E5AV M!'KQ9+ES^NNGLVPG:75EW8>QS:')W3VZNT=W)YFN6W>2_.'(N2.]DKK=T*-S MS?LD:0]'KEC[SC1<>Z0R5C'G55LG;6,Y*UMP4C)9WMQDB6)"TV*M.W6G7$L. MIM-N0V]H4JPKH\^6E :#7\H4)X],;NB62;&W8EC+E)"G8%Z"X6"DL<1Y*GQ# M%V!IGP*\"!JP'.,HH8T%8Q(RA._]N/P9,&FM5X64,\$E#89BW3#GN-5W7AD6 M#\87$!GEW:GQ#&O+3HOE+3T[##\^R=[8DMLYS8).IF(M>05TK*B/\.M,DP#H MG%%>* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5B'_2^FO-CT1=X=-8T\O1!BEHK M'O;^RPF+-9O\R-%8\>2SP:0)P:?EA6;/CO9NFJ:]PSLM_D/.? MK7/--;=,7I+VH_\W5_DMC)/Q]%PZC+N.HL?X;[:)'- MM[#/)73)>UYN1]76^T$D7O!9QP<&%Y_J?] MK-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,J^AV&V6PQ>J69? 7 MCX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@\;J!1Y['NXWE 0^L M"]CL0/YX'IBIN$^:0ERHY_U=3_ 102P,$% @ Q#1;59>* MNQS $P( L !?3T\$MP>:4#M.*2VBZD8_1!2:5K5N %( MMB6/:(7->=I3W;+T]! M;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B M':5_'B4?'D78FYJD6:>IK&HP=MX1PT$G53$WHI"/J:Q8;!EK '$NW2:9;/46PQF MN1BUMIS> A(H!"DHV1%[A$O\G7D(GP&LK\,S4-AB.G8RF2&]B]#V,YU#BG/]3(U45%K"FHO409.B1 MP74&0ZRQB28)UD-N5G0&[O+H YMRR"9JZJ8IGJ,.>%,.]D9/)508H'Q3F:B\ M]E-L.>F.7F=Z_S!YU!Y:YU;*O8=7LN48Y0]02P,$% @ Q#1;520> MFZ*M ^ $ !H !X;"]?+7_OR4Z?:!1W M;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9 MHIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJ MEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0 ( ,0T M6U5ED'F2&0$ ,\# 3 6T-O;G1E;G1?5'EP97-=+GAM;*V334[#,!"% MKQ)E6R4N+%B@IAM@"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/ M$;#HG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4 MZ]4SM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N M6%"*JX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC M JFQ R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1.;$$?\>=(\G=560C2&2FKW@A MLO7L^T%.6X.^D&PO=&AE M;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( ,0T6U5%PZ!Y@P4 % > 8 M " @0X( !X;"]W;W)K&PO&PO7W)E;',O M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " #$-%M599!YDAD! #/ P M$P @ '1$P 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 .."0 ) #X" ;%0 ! end XML 14 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 16 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 6 22 1 false 5 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://merck.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2227726d1_8k.htm mrk-20221026.xsd mrk-20221026_def.xml mrk-20221026_lab.xml mrk-20221026_pre.xml tm2227726d1_ex99-1.htm tm2227726d1_ex99-2.htm tm2227726d1_ex99-3.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 18 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2227726d1_8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 6, "dts": { "definitionLink": { "local": [ "mrk-20221026_def.xml" ] }, "inline": { "local": [ "tm2227726d1_8k.htm" ] }, "labelLink": { "local": [ "mrk-20221026_lab.xml" ] }, "presentationLink": { "local": [ "mrk-20221026_pre.xml" ] }, "schema": { "local": [ "mrk-20221026.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 68, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 4, "memberStandard": 1, "nsprefix": "mrk", "nsuri": "http://merck.com/20221026", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2227726d1_8k.htm", "contextRef": "From2022-10-26to2022-10-26", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://merck.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2227726d1_8k.htm", "contextRef": "From2022-10-26to2022-10-26", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 5, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "booleanItemType" }, "mrk_Sec0.500NotesDue2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "0.500% Notes due 2024" } } }, "localname": "Sec0.500NotesDue2024Member", "nsuri": "http://merck.com/20221026", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "domainItemType" }, "mrk_Sec1.375NotesDue2036Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "1.375% Notes due 2036" } } }, "localname": "Sec1.375NotesDue2036Member", "nsuri": "http://merck.com/20221026", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "domainItemType" }, "mrk_Sec1.875NotesDue2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "1.875% Notes due 2026" } } }, "localname": "Sec1.875NotesDue2026Member", "nsuri": "http://merck.com/20221026", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "domainItemType" }, "mrk_Sec2.500NotesDue2034Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2.500% Notes due 2034" } } }, "localname": "Sec2.500NotesDue2034Member", "nsuri": "http://merck.com/20221026", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://merck.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 19 0001104659-22-111729-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-111729-xbrl.zip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�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